Drugs / SRK-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05156034 | Dec 2021 → Sep 2022 | — | Sarkana Pharma Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156034 ↗ |
| Route | Intravenous | “Participants will receive IV doses of SRK-001.” NCT05156034 ↗ |